Abstract
Photodynamic therapy (PDT) is an approved promising new treatment modality for a variety of cancers. In combination with nanotechnology, PDT offers the lowest rates of side effects and reveals high treatment efficiency. This study aimed to design and develop a new formulation based on zinc oxide containing Manganese (III) Phthalocyanine Chloride (ZnO/MnPcCl NPs) for use in the PDT protocol and investigate its hemocompatibility with human blood. Additionally, the antitumor activity in mice using the Ehrlich solid tumor as an experimental model was examined. They were nonhemolytic and had no harmful effects on partial thromboplastin time and prothrombin time. ZnO/MnPcCl NPs in conjunction with laser (670 nm/0.6 j/cm(2)) had significantly better in vivo anticancer efficacy compared with pristine ZnO/MnPcCl NPs and laser. These findings confirm that ZnO/MnPcCl NPs could serve as an efficient and biocompatible PDT system for anticancer. Also, this study confirms that the combination between PDT and nanotechnology can improve the shortcomings of photodynamic therapy.